Kush has joined IQ Capital as an Associate and focuses on biotech and health investments. He is particularly fascinated by companies that are pioneering the intersection of innovative engineering and cutting edge biotechnology, whether in therapeutics or for wider applications. More recently, he has been diving deeper into computational approaches in drug discovery and development, with a particular interest protein design.
As an undergraduate and master’s student Kush specialised into Synthetic and Computational Biology at Imperial College. He has continued this into his PhD, working towards decoding molecular mechanisms of host-microbiota communication using synthetic biology approaches, including 3D printing bacterial communities and high throughput CRISPR screening. His doctoral work has been a joint project split between Imperial and Harvard Medical School.